DrugPatentWatch Database Preview

Details for Patent: 9,095,615

Which drugs does patent 9,095,615 protect, and when does it expire?

Patent 9,095,615 protects HYSINGLA and is included in one NDA.

This patent has one hundred and sixty-five patent family members in thirty-nine countries.

Summary for Patent: 9,095,615

Title:	Tamper resistant dosage forms
Abstract:	The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
Inventor(s):	McKenna; William H. (Yonkers, NY), Mannion; Richard O. (Furlong, PA), O'Donnell; Edward P. (Basking Ridge, NJ), Huang; Haiyong H. (Princeton, NJ)
Assignee:	PURDUE PHARMA L.P. (Stamford, CT) PURDUE PHARMACEUTICALS L.P. (Wilson, NC)
Application Number:	14/515,921
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,095,615
Patent Claim Types: see list of patent claims	Composition; Dosage form; Process; Device;

Drugs Protected by US Patent 9,095,615

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Purdue Pharma Lp	HYSINGLA	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	206627-001	Nov 20, 2014		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Purdue Pharma Lp	HYSINGLA	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	206627-002	Nov 20, 2014		RX	Yes	No	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Purdue Pharma Lp	HYSINGLA	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	206627-003	Nov 20, 2014		RX	Yes	No	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Purdue Pharma Lp	HYSINGLA	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	206627-004	Nov 20, 2014		RX	Yes	No	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 9,095,615

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
8,834,925	Tamper resistant dosage forms	➤ Sign Up
9,770,416	Tamper resistant dosage forms	➤ Sign Up
9,763,933	Tamper resistant dosage forms	➤ Sign Up
9,770,417	Tamper resistant dosage forms	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 9,095,615

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	2355	➤ Sign Up
Argentina	062511	➤ Sign Up
Argentina	103463	➤ Sign Up
Austria	11571	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 9,095,615

For more information try a trial or see the plans and pricing